Speakers

Expand/Collapse

Dean Sheppard
Chief of Pulmonary, Critical Care, Allergy & Sleep & Director of Lung Biology Center
University of California, San Francisco

Day One

Wednesday August 18, 2021

9:15 am | Keynote: Targeting Integrin Tethering of Airway Smooth Muscle to Treat Exaggerated Airway Narrowing

Katerina Leftheris
Vice President & Head of Chemistry
Pliant Therapeutics

Day Two

Thursday August 19, 2021

9:15 am | Developing Selective, Orally Bioavailable Integrin Inhibitors

Kevin Hart
Principal Scientist, Inflammation
Pfizer

Day Two

Thursday August 19, 2021

2:50 pm | Cell-Specific Roles of Integrin Alpha V in Regulation of Inflammation & Fibrosis

Scott Turner
Vice President of Translational Sciences
Pliant Therapeutics

Day One

Wednesday August 18, 2021

10:15 am | PLN-74809, an Oral, Dual-Selective Inhibitor of αvβ6 & αvβ1 Integrins for the Treatment of IPF & PSC

Day Two

Thursday August 19, 2021

12:15 pm | Panel Discussion: Equipping Your Translational Confidence

Rajita Pappu
Scientist
Genentech

Susanne Kossatz
Assistant Professor
Technical University Munich

Day Two

Thursday August 19, 2021

3:20 pm | Targeted Delivery of the Organometallic Ferrocene Via Highly Selective ανβ3, ανβ6, or α5β1-Targeting Ligands

Natalia Blanco
Principal Scientist
Morphic Therapeutics

Day Two

Thursday August 19, 2021

2:20 pm | Inhibition of Integrin αvβ8 Enhances Immune Checkpoint Induced Anti-Tumor Immunity by Acting Across Immunologic Synapse

Bruce Rogers
Chief Scientific Officer
Morphic Therapeutics

Day Two

Thursday August 19, 2021

10:15 am | An Oral Selective α4β7 Integrin Inhibitor for Inflammatory Bowel Disease: MORF-057

Upendra Marathi
President & Chief Executive Officer
7 Hills Pharma

Day Two

Thursday August 19, 2021

12:15 pm | Panel Discussion: Equipping Your Translational Confidence

Steve Kerrigan
Head, Cardiovascular Infection Research Group & Chief Scientific Officer
RCSI University of Medicine and Health Sciences & Inthelia Therapeutics

Day One

Wednesday August 18, 2021

9:45 am | Integrins as Novel Targets in the Treatment of Severe Bloodstream Infection & Sepsis

Peter Vanderslice
Texas Heart Institute
& Co-Founder, 7 Hills Pharma

Day Two

Thursday August 19, 2021

11:45 am | Small Molecule Integrin Activators as Immune Stimulants – From Discovery to the Clinic

Alan Stitt
Chief Scientific Officer
Oxurion

Day One

Wednesday August 18, 2021

4:50 pm | Chair’s Closing Remarks & End of Day One

11:10 am | Targeting RGD-Binding Integrins as an Integrative Therapy for Diabetic Retinopathy & Neovascular Age-Related Macular Degeneration

9:00 am | Chair’s Opening Remarks

Rik Derynck
Professor - Departments of Cell, Tissue Biology & Anatomy
University of California San Francisco

Kairbaan Hodivala-Dilke
Deputy Director & Professor
Barts Cancer Institute

Day One

Wednesday August 18, 2021

2:10 pm | Low Dose Integrin Targeting & Enhancing Cancer Therapy

Zofia Ostrowska- Podhorodecka
Researcher
University of Toronto

Day One

Wednesday August 18, 2021

12:10 pm | Understanding the Mechanism Behind Vimentin’s Control on the β1 Integrin Signaling Systems

Horst Kessler
Senior Fellow
Technical University Munich

Day Two

Thursday August 19, 2021

10:45 am | Design of Selective Ligands for RGD-Recognizing Integrins

Bálint Mészáros
Postdoctoral Research Fellow
European Molecular Biology Laboratory

Day One

Wednesday August 18, 2021

3:50 pm | Integrins are Targeted by SARS-CoV-2 Cell Attachment Modulating Endocytosis & Autophagy in Host Cells

Bernhard Wehrle- Haller
Professor
University of Geneva

Day Two

Thursday August 19, 2021

9:45 am | Integrin Specificity at the Level of Ligands & Intracellular Adapters

Peter Kaiser
Professor of Ophthalmology
Cleveland Clinic

Day One

Wednesday August 18, 2021

2:40 pm | Integrin Modulation & Retinal Vascular Disease

Koichi Yuki
Senior Associate in Cardiac Anesthesia
Boston Children’s Hospital

Day One

Wednesday August 18, 2021

4:20 pm | Integrin Alpha X Regulates Hematopoietic Stem & Progenitor Cells Under Stress

Julien Marie
Dean of the Tumor Escape Resistance & Immunity Department
Inserm

Day One

Wednesday August 18, 2021

11:40 am | Targeting αvβ8 Integrins for Innovative Immunotherapies in Cancer

Mary Keir
Senior Scientist
Genentech

Fernando Rock
Vice President Drug Discovery
Pliant Therapeutics

Bill DeGrado
Professor & Vice Chair - Pharmaceutical Chemistry
University of California, San Francisco

Sam Shrivastava
Chief Executive Officer
Venn Therapeutics

Day Two

Thursday August 19, 2021

1:50 pm | Integrin avb8 Expression Levels as a Biomarker for Cancer Treatment

12:15 pm | Panel Discussion: Equipping Your Translational Confidence